Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism

[1] Orr WC(2005)Night-time gastro-oesophageal reflux disease: prevalence, hazards, and management Eur J Gastroenterol Hepatol 17 113-120

[2] Lindberg P(2003)Esomeprazole - enhanced bio-availability, specificity for the proton pump and inhibition of acid secretion Aliment Pharmacol Ther 17 481-488

[3] Keeling D(1992)Appropriate acid suppression for the management of gastro-oesophageal reflux disease Digestion 51 59-67

[4] Fryklund J(2001)Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis J Gastroenterol Hepatol 16 1191-6

[5] Andersson T(1998)Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects Gastroenterology 115 1335-1339

[6] Lundborg P(2003)Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study Am J Gastroenterol 98 2616-2620

[7] Carlsson E(2000)Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg during single and repeated administration Gut 47 A63-867

[8] Bell NJV(2000)Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease Aliment Pharmacol Ther 14 861-958

[9] Burget D(2002)Effect of esomeprazole 40 mg vs. omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease Dig Dis Sci 47 954-23

[10] Howden CW(2000)Esomeprazole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mg Gastroenterology 118 A22-406

[1] Orr WC(2005)Night-time gastro-oesophageal reflux disease: prevalence, hazards, and management Eur J Gastroenterol Hepatol 17 113-120

[2] Lindberg P(2003)Esomeprazole - enhanced bio-availability, specificity for the proton pump and inhibition of acid secretion Aliment Pharmacol Ther 17 481-488

[3] Keeling D(1992)Appropriate acid suppression for the management of gastro-oesophageal reflux disease Digestion 51 59-67

[4] Fryklund J(2001)Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis J Gastroenterol Hepatol 16 1191-6

[5] Andersson T(1998)Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects Gastroenterology 115 1335-1339

[6] Lundborg P(2003)Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study Am J Gastroenterol 98 2616-2620

[7] Carlsson E(2000)Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg during single and repeated administration Gut 47 A63-867

[8] Bell NJV(2000)Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease Aliment Pharmacol Ther 14 861-958

[9] Burget D(2002)Effect of esomeprazole 40 mg vs. omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease Dig Dis Sci 47 954-23

[10] Howden CW(2000)Esomeprazole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mg Gastroenterology 118 A22-406